First-line obinutuzumab for follicular lymphoma

被引：0
|
作者：
Baker, Holly
机构：
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 11期
关键词：
D O I：
10.1016/S1470-2045(17)30781-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E648 / E648
页数：1
相关论文
共 50 条
  • [41] Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Kumar, Anita
    Soumerai, Jacob
    Abramson, Jeremy S.
    Barnes, Jeffrey A.
    Caron, Philip
    Chhabra, Shalini
    Chabowska, Maria
    Dogan, Ahmet
    Falchi, Lorenzo
    Grieve, Clare
    Haydu, J. Erika
    Johnson, Patrick Connor
    Joseph, Ashlee
    Kelly, Hailey E.
    Labarre, Alyssa
    Lue, Jennifer Kimberly
    Martignetti, Rosalba
    Mi, Joanna
    Moskowitz, Alison
    Owens, Colette
    Plummer, Sean
    Puccio, Madeline
    Salles, Gilles
    Seshan, Venkatraman
    Simkins, Elizabeth
    Slupe, Natalie
    Zhang, Honglei
    Zelenetz, Andrew D.
    BLOOD, 2025, 145 (05) : 497 - 507
  • [42] The role of obinutuzumab in the management of follicular lymphoma
    O'Nions, Jenny
    Townsend, William
    FUTURE ONCOLOGY, 2019, 15 (31) : 3565 - 3578
  • [43] Is obinutuzumab cost-effective in the first-line treatment of CLL?
    Veenstra, David Leroy
    Reyes, Carolina M.
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A plus O) plus /- radiotherapy (RT): Results from the FLUORO study
    Chong, Geoffrey
    Lee, Denise
    Lee, Sze Ting
    Grobler, Anneke
    Khor, Richard
    Campbell, Belinda A.
    Thachil, Thanuja
    Manos, Kate
    Martynchyk, Arina
    Douglas, Genevieve
    Keane, Colm
    Palmer, Jodie
    Hawkes, Eliza Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma
    To, Tu My
    Dawson, Keith L.
    Masaquel, Anthony S.
    Seetasith, Arpamas
    BLOOD, 2019, 134
  • [46] Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
    Anne-Sophie AS Michallet
    Laure L Lebras
    Deborah D Bauwens
    Fadhela F Bouafia-Sauvy
    Françoise F Berger
    Christelle C Tychyj-Pinel
    Anne A D’Hombres
    Gilles G Salles
    Bertrand B Coiffier
    Journal of Hematology & Oncology, 6
  • [47] Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?
    Fisher, Richard I.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (11): : 1414 - 1416
  • [48] Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics
    Manaka Muneishi
    Ayaka Nakamura
    Katsumi Tachibana
    Junko Suemitsu
    Shinji Hasebe
    Kazuto Takeuchi
    Yoshihiro Yakushijin
    International Journal of Clinical Oncology, 2018, 23 : 375 - 381
  • [49] Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
    Michallet, Anne-Sophie A. S.
    Lebras, Laure L.
    Bauwens, Deborah D.
    Bouafia-Sauvy, Fadhela F.
    Berger, Francoise F.
    Tychyj-Pinel, Christelle C.
    D'Hombres, Anne A.
    Salles, Gilles G.
    Coiffier, Bertrand B.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [50] Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation
    Emmanuel Bachy
    Kaspar Rufibach
    Joana Parreira
    Aino Launonen
    Tina Nielsen
    Allan Hackshaw
    Advances in Therapy, 2021, 38 : 3489 - 3505
12345